OlomoucineA potent and selective inhibitor of Cdc2 and ERK1

Olomoucine (CAS 101622-51-9)

Olomoucine | CAS 101622-51-9 is rated 5.0 out of 5 by 1.
  • y_2019, m_11, d_19, h_17
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.3-b1
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_3509, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 91ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine
Application: A potent and selective inhibitor of Cdc2 and ERK1
CAS Number: 101622-51-9
Purity: ≥98%
Molecular Weight: 298.34
Molecular Formula: C15H18N6O
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Olomoucine is a purine that acts as a competitive inhibitor of a variety of cell cycle regulating proteins with high specificity, which leads to the blockage of some cell cycle steps. The compound inhibits: Cdc2/cyclin B, Cdk2/cyclin A and Cdk2/cyclin E kinases, the brain Cdk5/p35 kinase and the ERK1/MAP-kinase. Olomoucine does not significantly inhibit Cdk4/cyclin D1 and Cdk6/cyclin D3 kinases. The compound can induce cell arrest at G1/S and the G2/M, due to its effect on Ckd2 and Cdcd2. Olomoucine also behaves as a competitive inhibitor for ATP and as a non-competitive inhibitor for histone H1 in terms of being Cdk substrates.


References

1. Veselý, J., et al. 1994. Eur. J. Biochem. 224: 771-786. PMID: 7925396
2. Abraham, R.T., et al. 1995. Biol. Cell. 83: 105-120. PMID: 7549905
3. Korinkova, G., et al. 2010. Neoplasma. 57: 161-169. PMID: 20099981

Physical State :
Solid
Solubility :
Soluble in DMSO (32 mg/ml), ethanol (7 mg/ml), water (0.5 mg/ml), DMF (30 mg/ml), and 1:1 DMF:PBS(pH 7.2) (~0.5 mg/ml).
Storage :
Store at -20° C
Melting Point :
120-130° C
Boiling Point :
579.58° C at 760 mmHg (Predicted)
Density :
1.36 g/cm3
Refractive Index :
n20D 1.69 (Predicted)
IC50 :
p34cdk1/cyclin B: IC50 = 7 µM; p33cdk2/cyclin A: IC50 = 7 µM; p33cdk2/cyclin E: IC50 = 7 µM; p33cdk5/p35 : IC50 = 3 µM; p44 MAP kinase: IC50 = 25 µM; p34cdk4/cyclin D: IC50 = >1 mM; p40cdk6/cyclin D3: IC50 = >250 µM
pK Values :
pKb: 4.87 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
4592
MDL Number :
MFCD00189360
SMILES :
CN1C=NC2=C1N=C(N=C2NCC3=CC=CC=C3)NCCO

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Olomoucine  Product Citations

See how others have used Olomoucine. Click on the entry to view the PubMed entry .

Citations 1 to 9 of 9 total

PMID: # 17001081  Canela, N. et al. 2006. J. Biol. Chem. 281: 35942-35953.

PMID: # 12740381  Eide, T. et al. 2003. J. Biol. Chem. 278: 26750-26756.

PMID: # 12351630  Hou, S.T. et al. 2002. J Biol Chem. 277: 48764-48770.

PMID: # 11741900  Reddy, TR. et al. 2002. J. Biol. Chem. 277: 5778-5784.

PMID: # 11679575  Ye, K. et al. 2001. J. Biol. Chem. 276: 46697-46700.

PMID: # 10660590  Romanowski, P. et al. 2000. J. Biol. Chem. 275: 4239-4243.

PMID: # 10318807  Gabrielli, BG. et al. 1999. J. Biol. Chem. 274: 13961-13969.

PMID: # 9353326  Gabrielli, BG. et al. 1997. J. Biol. Chem. 272: 28607-28614.

PMID: # 25715600  Ermakov, AM. et al. Biofizika. 59: 552-7.

Citations 1 to 9 of 9 total

How is a stock solution made for this product?

Asked by: hawkeye11
Thank you for your question. A stock solution of Olomoucine, sc-3509A, may be made by dissolving the olomoucine in an organic solvent purged with an inert gas. Olomoucine is soluble in organic solvents such as ethanol, DMSO, and dimethylformamide (DMF). The solubility of olomoucine in these solvents is approximately 10, 20, and 30 mg/ml, respectively.
Answered by: TechService7
Date published: 2017-01-25
  • y_2019, m_11, d_19, h_17CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.3-b1
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_3509, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 80ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Eide Eide, et. al. (PubMed ID 12740381) used olomoucine, a specific Cdc inhibitor, to inhibit replication in order to confirm that 32P labeling in G1 nuclei was due to the initiation of replication. -SCBT Publication Review
Date published: 2015-01-12
  • y_2019, m_11, d_19, h_17
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.3-b1
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_3509, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 32ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.